BRAVE-3 study is the first to test the influence of high-dose clopidogrel on the value of abciximab exclusively in patients with ST-elevation myocardial infarction (STEMI), a serious form of heart attack.Study is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago.Is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the of Cardiology (ACC)."Acute myocardial infarction is a major medical problem, and the present study will help to define the optimal treatment strategy," said Julinda Mehilli, MD, an associate professor and staff cardiologist at Deutsches Herzzentrum, Technical University, Munich, Germany.Without abciximab would certainly be more cost-effective and reduce the risk of bleedingplications.For the study Dr.And colleagues recruited 800 patients with STEMI who were undergoing PCI.Patients were pretreated with 600 mg of clopidogrel and then randomly assigned to receive intravenous abciximab or a placebo during the procedure.The study was designed primarily topare how the two treatment strategies affected the final amount of heart attack damage, as gauged by blood flow in the heart muscle on a nuclear scan five to 10 days later.Found no difference between the two groups: The damage involved 10 percent of the left ventricle, on average, in the abciximab group and 9 percent of the left ventricle in the placebo group.Addition, the 30-daybined rates of death, heart attack, stroke and urgent repeat coronary procedures were similar in the two groups (5 percent and 3.Respectively)."For patients with acute ST-elevation myocardial infarction undergoing primary coronary intervention after pre-treatment with a 600-mg loading dose of clopidogrel, the additional use of abciximab is not associated with any measurable benefit after 30 days," Dr.Said.Dr.Present the results of the BRAVE-3 study on Sunday, March 30 at 8:30 a.CDT in the Grand Ballroom, S100.About SCAI Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in over 60 nations.Is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care.Annual meeting has be the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.About ACC The of Cardiology is leading the way to optimal cardiovascular care and disease prevention.Is a 34,000-member nonprofit medical society and bestows the credential Fellow of the of Cardiology upon physicians who meet its stringent qualifications.College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research.ACC provides professional education and operates national registries for the measurement and improvement of quality care.CONTACT: Kathy Boyd David of SCAI, cell, +1-717-422-1181, ; orAmy Murphy of ACC, +1-202-375-6476, cell, +1-240-328-4549, amurphy@acc.Conditions of use apply Copyright 2008 PR Newswire Association LLC.Rights reserved.United Business Mediapany CLINICAL TRIAL RESULTS ARCHIVE 2008: 2007: 2006: MORE NEWS RESOURCES Services Recent Searches Recently Approved Join Drugs to see what benefits you can get by joining our .The most popular,prehensive, and up-to-date source of drug information online.Advice on more than 24,000 prescription drugs and over-the-counter medicines for consumers and professionals .Top 10 Searches In The Pipeline - - - - - - - - - - - The drugs drug database is powered by MicromedexTM, Facts &parisonsTM and MultumTM.Last updated 6 March 2008.Read more [gastrointestinal cancer] targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase ii study of depot octreotide with bevacizumab and pegylated interferon alfa-2b
Get more Lamotrigine(lamotrigine) tablet [teva pharmaceuticals usa]
